Rocket One Inc. (Hoth Therapeutics, Inc.)

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative and impactful treatments to improve patient quality of life. While its parent company, Rocket One Inc., has recently pivoted its primary focus to the space economy and nanomagnetic AI chip technology, Hoth Therapeutics continues its mission in early-stage pharmaceutical research and development as a wholly-owned subsidiary. The company's headquarters are located in Hoboken, New Jersey.

Hoth Therapeutics' pipeline includes therapeutic candidates targeting various medical conditions such as oncology supportive care, oncology, neurodegenerative diseases, metabolic disorders, and inflammatory and dermatologic conditions. Key programs feature HT-001, a topical treatment for skin toxicities associated with cancer therapy; HT-KIT, an oncology platform for mast cell-derived cancers which has received FDA Orphan Drug Designation; HT-ALZ, a therapeutic candidate for Alzheimer's disease; and a GDNF-based program for obesity and metabolic dysfunction.

In a significant corporate development, Hoth Therapeutics, Inc. officially changed its legal name to Rocket One Inc. on May 27, 2026, and its Nasdaq ticker symbol transitioned from HOTH to RKTO on May 28, 2026. This strategic repositioning by the parent entity means that Hoth Therapeutics' biotechnology programs now operate under a subsidiary structure. Robb Knie serves as the Chief Executive Officer and Chairman of the company.